Press Releases July 8, 2026 07:00 AM

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

Sono-Tek Reports Strong Q1 Fiscal 2027 Results with 10% Revenue Growth and 57% Gross Margin Fueled by Medical Sector Demand

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
SOTK

Sono-Tek Corporation reported a 10% increase in net sales to $5.66 million for the first quarter fiscal 2027, alongside an expansion in gross margin from 52% to 57%. Operating income surged 86% and net income increased 53%, driven primarily by strong demand in the medical devices market including specialty stent coating and drug-eluting balloon platforms. The company expects continued revenue growth in the first half of fiscal 2027 and maintains a positive outlook supported by the medical sector and higher-value production systems.

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results
SOTK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Revenue grew 10% to $5.66 million driven by strong medical device sector demand globally.
  • Gross margin expanded to 57% due to favorable product and geographic mix, including lower commission expenses in U.S. sales.
  • Backlog increased slightly and the company maintains a strong balance sheet with $16.65 million in cash and no debt.
  • Sectors impacted include medical devices, microelectronics, alternative energy, and advanced industrial manufacturing, emphasizing precision ultrasonic coating technologies.

Revenue Increased 10%; Gross Margin Expanded to 57%; Operating Income Increased 86%; Net Income Increased 67%

Anticipating Continued Revenue Growth in 1H 2027 Driven by Strong Medical Sector and Higher Value Production Systems

MILTON, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Sono-Tek Corporation (Nasdaq: SOTK), a leading developer and manufacturer of precision ultrasonic coating systems, today reported financial results for the first quarter of fiscal 2027, ended May 31, 2026.

First Quarter Fiscal 2027 Highlights

  • Net sales increased 10% to $5.66 million
  • Gross margin expanded to 57% from 52%
  • Gross profit increased 21% to $3.21 million
  • Operating income increased 86% to $897,000
  • Net income increased 53% to $741,000, or $0.05 per diluted share
  • Cash, cash equivalents, and marketable securities increased to $16.65 million with no debt
  • Backlog increased to approximately $7.73 million

Steve Harshbarger, CEO & President of Sono-Tek, stated:

"Fiscal 2027 is off to a strong start with double-digit revenue growth, meaningful margin expansion, and improved profitability, reflecting disciplined execution across our operations and the continued success of our strategy of focusing on higher-value production systems in advanced technology markets, particularly medical devices.

"Our medical business was the primary growth driver this quarter, with strong demand for specialty stent coating systems and Drug-Eluting Balloon platforms across the U.S., Europe, and Asia. This exceptional mix of business-including a higher concentration of medical systems, shipments of higher-value production platforms, and a greater proportion of U.S. based sales with lower distributor commission expenses, was a significant contributor to our gross margin expansion.  While we are very pleased with these results, product mix, geographic mix, and shipment timing naturally fluctuate from quarter to quarter, and we would not expect this level of gross margin to be representative of every future quarter.  Our technology is increasingly being selected for applications requiring highly controlled, repeatable thin-film coatings, positioning Sono-Tek to benefit as manufacturing precision requirements continue to increase across multiple industries.”

"Looking ahead, we remain focused on expanding our installed base of production systems, supporting customers as they scale from development into commercial manufacturing, and investing in the engineering and commercial capabilities that will drive our next phase of growth. The Company continues to project revenue growth during the first half of fiscal 2027, supported by strong medical demand and continued shipments of higher-value production systems, and we maintain our previously communicated expectation of flat to modest revenue growth for the full fiscal year. This full-year outlook primarily reflects the timing of several large production platform orders. As these higher-value production systems become a larger portion of our business, quarterly revenue may increasingly be influenced by shipment timing. Our strong balance sheet provides the flexibility to execute these priorities while continuing to create long-term value for shareholders."

Dr. Christopher L. Coccio, Executive Chairman, added:

"Our first quarter results reinforce the long-term strength of Sono-Tek's ultrasonic coating technology platform and validate the strategic direction that we have pursued for many years. As precision manufacturing requirements continue to increase across advanced industries, we believe we are well positioned to expand our leadership through continued innovation and differentiated application expertise.”

"We have spent decades building differentiated technology, deep application expertise, and lasting customer relationships that continue to position us for future success. We believe these enduring strengths, together with disciplined investment and a strong financial foundation, position Sono-Tek to capitalize on attractive long-term growth opportunities while creating lasting shareholder value."

First Quarter Fiscal 2027 Results

Net sales increased 10% to $5.66 million, driven by strong Medical demand, partially offset by lower Alternative Energy shipments compared with the prior-year period.

Gross profit increased 21% to $3.21 million, with gross margin expanding from 52% to 57% due to favorable product mix and higher-value system shipments.

Operating expenses increased 6% to $2.32 million due to continued investment in sales, engineering, and business development initiatives.

Operating income increased 86% to $897,000.

Net income increased 53% to $741,000, or $0.05 per diluted share.

First Quarter Fiscal 2027 Results – (compared with the prior year period)

 Three Months Ended May 31,Change  2026  2025 $%Net Sales$5,661,000 $5,133,000 528,000 10%Gross Profit 3,214,000  2,665,000 549,000 21%Gross Margin 57%  52%    Operating Income$897,000 $483,000 414,000 86%Operating Margin 16%  9%    Net Income$741,000 $485,000 256,000 53%Net Margin 13%  9%    Basic Earnings Per Share$0.05 $0.03    Diluted Earnings Per Share$0.05 $0.03    Weighted Average Shares -Basic 15,713,000  15,734,000    Weighted Average Shares - Diluted 15,737,000  15,749,000    


First Quarter Fiscal 2027 Product and Market Highlights

Market Sales

  • Medical: $3.95 million vs. $809,000
  • Electronics/Microelectronics: $863,000 vs. $943,000
  • Alternative Energy/Clean: $319,000 vs. $3.25 million
  • Industrial: $530,000 vs. $119,000
  • Emerging R&D and Other: $3,000 vs. $14,000

Medical growth was driven by specialty stent coating systems in the U.S. and Drug-Eluting Balloon platforms across the U.S., China, and Europe. Alternative Energy declined due to reduced electrolysis demand and the absence of solar shipments. Industrial growth reflected system upgrades and R&D nano-coating applications.

Product Sales

  • Fluxing Systems: $92,000 vs. $152,000
  • In-Line Coating Systems: $2.16 million vs. $3.05 million
  • Multi-Axis Coating Systems: $2.08 million vs. $677,000
  • OEM Systems: $231,000 vs. $130,000
  • Spare Parts, Services and Other: $1.10 million vs. $1.12 million
  • Total Net Sales: $5.66 million vs. $5.13 million

Multi-Axis growth was driven by strong demand across multiple end markets. In-Line declined due to reduced clean energy shipments, including the absence of prior-year solar system deliveries. OEM Systems increased on semiconductor and fluxer OEM demand, while services remained stable.

Balance Sheet, Backlog and Outlook

Balance Sheet: Cash, cash equivalents, and marketable securities totaled $16.65 million, compared with $14.81 million at the prior year end. The Company had no outstanding debt.

Backlog: Combined equipment and service-related backlog at May 31, 2026 was $7.73 million, compared to backlog of $7.48 million at May 31, 2025, an increase of $250,000, or 3%. Backlog was down $1.39 million compared to the fiscal 2026 year-end level of $9.12 million.

Outlook: Sono-Tek anticipates continued revenue growth and profitability in the first half of fiscal year 2027 compared to the first half of fiscal year 2026, driven by expanding demand in the medical sector and continued adoption of high value production-scale coating systems across multiple end markets. Total fiscal year 2027 revenue is currently projected to be relatively flat to modestly higher compared to fiscal year 2026, as visibility beyond the first half remains limited due to continued uncertainty in certain clean energy sectors and the timing of shipments for higher value production scale platforms.

About Sono-Tek

Sono-Tek Corporation is a global leader in the design and manufacture of ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts used in diverse industries including microelectronics, alternative energy, medical devices, advanced industrial manufacturing, and research and development sectors worldwide. Sono-Tek's inroads into the clean energy sector have shown transformative results in next-gen solar cells, fuel cells, green hydrogen generation, and carbon capture applications.

Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability. Our comprehensive suite of thin film coating solutions and application consulting services are expected to generate unparalleled results for our clients and help some of the world's most promising companies achieve technological breakthroughs and bring them to the market. We strategically deliver our products to customers through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives, ensuring efficient market reach across diverse sectors around the globe.

Our solutions are environmentally friendly, efficient and highly reliable, and enable dramatic reductions in overspray, savings in raw material, water and energy usage and provide improved process repeatability, transfer efficiency, high uniformity and reduced emissions.

Our growth strategy is focused on leveraging our innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop thin film coating technologies that enable better outcomes for our customers’ products and processes. For further information, visit www.sono-tek.com

Safe Harbor Statement

This news release contains forward looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These “forward-looking statements’ are based on currently available competitive, financial and economic data and our operating plans.  They are inherently uncertain, and investors must recognize that events could turn out to be significantly different from our expectations and could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions, including political, regulatory, tax, competitive and technological developments affecting our operations or the demand for our products; inflationary and supply chain pressures; continued strength of sales to the medical device and electronics markets; increased private and public funding for the clean energy sector;  continued strong demand for Sono-Tek’s suite of thin film coating solutions and application consulting services in the clean energy and other markets; maintenance of order backlog; evolving tariff policies; timely development and market acceptance of new products and continued customer validation of our coating technologies; adequacy of financing; capacity additions, the ability to enforce patents; maintenance of operating leverage; consummation of order proposals; timing of large orders and completion on schedule and on budget; successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems; and realization of first half and annual revenues and profitability within the forecasted ranges of guidance. We undertake no obligation to update any forward-looking statement.

For more information:

Sono-Tek Corp.
Stephen J. Bagley
Chief Financial Officer
Ph: (845) 795-2020
[email protected]

Investor Relations
Kirin Smith, President
PCG Advisory, Inc.
[email protected]

- Financial Tables to follow –


  SONO-TEK CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS     May 31, 2026  February 28,   (Unaudited)  2026 ASSETS        Current Assets:        Cash and cash equivalents $8,982,075  $7,339,403 Marketable securities  7,669,872   7,469,649 Accounts receivable (less allowance of $12,225, respectively)  1,264,932   3,350,953 Inventories  4,063,132   3,923,350 Prepaid expenses and other current assets  659,518   743,295 Total current assets  22,639,529   22,826,650          Land  250,000   250,000 Buildings, equipment, furnishings and leasehold improvements, net  2,138,226   2,173,443 Intangible assets, net  27,892   29,791 Deferred tax asset  809,182   1,141,611          TOTAL ASSETS $25,864,829  $26,421,495          LIABILITIES AND STOCKHOLDERS’ EQUITY                 Current Liabilities:        Accounts payable $935,442  $1,038,885 Accrued expenses  2,088,229   2,227,401 Customer deposits  2,006,896   3,069,743 Income taxes payable  147,984   255,398 Total current liabilities  5,178,551   6,591,427          Deferred tax liability  75,238   55,909 Total liabilities  5,253,789   6,647,336          Commitments and Contingencies (Note 10)  -   -          Stockholders’ Equity                 Common stock, $.01 par value; 25,000,000 shares authorized, 15,716,723 and 15,710,389 issued and outstanding as of May 31, 2026 and February 28, 2026  157,167   157,104 Additional paid-in capital  10,282,508   10,186,858 Accumulated earnings  10,171,365   9,430,197 Total stockholders’ equity  20,611,040   19,774,159          TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $25,864,829  $26,421,495 


See notes to unaudited condensed consolidated financial statements.


 SONO-TEK CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)   Three Months Ended May 31,   2026  2025        Net Sales $5,661,159  $5,132,773 Cost of Goods Sold  2,447,241   2,468,259 Gross Profit  3,213,918   2,664,514          Operating Expenses        Research and product development costs  616,982   668,470 Marketing and selling expenses  1,024,984   858,151 General and administrative costs  674,792   654,525 Total Operating Expenses  2,316,758   2,181,146          Operating Income  897,160   483,368          Interest and Dividend Income  114,624   142,098 Net unrealized (loss) on marketable securities  (26,271)  (21,923)         Income Before Income Taxes  985,513   603,543          Income Tax Expense  244,345   118,558          Net Income $741,168  $484,985          Basic Earnings Per Share $0.05  $0.03          Diluted Earnings Per Share $0.05  $0.03          Weighted Average Shares - Basic  15,713,185   15,733,955          Weighted Average Shares - Diluted  15,737,276   15,748,556 


See notes to unaudited condensed consolidated financial statements.


SONO-TEK CORPORATION
PRODUCT, MARKET, AND GEOGRAPHIC SALES
(Unaudited)

Product Sales:

  Three Months Ended May 31, Change  2026  % of total 2025  % of total $  %Fluxing Systems $92,000  2% $152,000  3%  (60,000) (39%)In-Line Coating Systems  2,159,000  38%  3,054,000  59%  (895,000) (29%)Multi-Axis Coating Systems  2,075,000  37%  677,000  13%  1,398,000  206%OEM Systems  231,000  4%  130,000  3%  101,000  78%Spare Parts, Services and Other  1,104,000  20%  1,120,000  22%  (16,000) (1%)TOTAL $5,661,000    $5,133,000    $528,000  10%


Market Sales:
 

  Three Months Ended May 31, Change  2026  % of total 2025  % of total $  %Electronics/Microelectronics $863,000  15% $943,000  19%  (80,000) (8%)Medical  3,946,000  70%  809,000  16%  3,137,000  388%Alternative Energy/Clean  319,000  6%  3,248,000  63%  (2,929,000) (90%)Emerging R&D and Other  3,000  0%  14,000  0%  (11,000) (79%)Industrial  530,000  9%  119,000  2%  411,000  345%TOTAL $5,661,000    $5,133,000    $528,000  10%


Geographic Sales:

  Three Months Ended        May 31,  Change  2026  2025  $  %U.S. & Canada $3,530,000  $3,543,000  $(13,000) 0%Asia Pacific (APAC)  738,000   597,000   141,000  24%Europe, Middle East, Africa (EMEA)  930,000   897,000   33,000  4%Latin America  463,000   96,000   367,000  382%TOTAL $5,661,000  $5,133,000  $528,000  10%

Risks

  • Revenue and profitability depend on fluctuating product mix, geographic sales distribution, and shipment timing which may cause quarter-to-quarter variation.
  • Uncertainty in the clean energy sector demand and timing of large high-value production platform shipments may limit revenue visibility beyond first half 2027.
  • Risks include potential impacts from broader economic conditions, supply chain pressures, tariff policies, and technological developments affecting demand for ultrasonic coating solutions.

More from Press Releases

Performance Shipping Inc. Secures Substantially Improved Terms and Extension of Existing Nordea Bank Facility Jul 8, 2026 Decent Holding Provides Business Update: Paid Member Base Reaches Nearly 150,000, Underscoring the Strength of Its Nationwide Community Healthcare Platform Jul 8, 2026 NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board Jul 8, 2026 CCHH CEO Announces Planned Purchase of US$10 Million to US$30 Million of Company Shares at Not Less Than US$1.00 Per Share, Reinforcing Long-Term Commitment to Strategic Growth Jul 8, 2026 Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact Jul 8, 2026